AbbVie faces a critical transition as biosimilar competition erodes Humira revenue. The pharmaceutical giant has built a diversified pipeline to offset this decline. Investors are watching whether new drugs can replace the $6.4 billion annual Humira franchise.
The setup
AbbVie is a research-based biopharmaceutical company headquartered in North Chicago, Illinois. The company markets drugs across immunology, oncology, neuroscience, and eye care. Its $54 billion acquisition of Allergan in 2020 added the aesthetics franchise Botox and expanded the gastrointestinal portfolio.
The central challenge for AbbVie is the Humira patent cliff. The rheumatoid arthritis and Crohn’s disease blockbuster generated $6.4 billion in U.S. sales in 2025, down from peak levels above $20 billion. Multiple biosimilar competitors now capture significant market share. AbbVie has responded by growing Skyrizi and Rinvoq, two next-generation immunology therapies.
Key numbers
| ABBV share price (August 2026) | $205.00 |
| Dividend yield | 3.2% |
| Annual dividend per share | $6.56 |
| Consecutive years of dividend increases | 52 |
| Skyrizi 2025 global sales | $11.7 billion |
| Rinvoq 2025 global sales | $5.3 billion |
| Humira 2025 U.S. sales | $6.4 billion |
| Market capitalization | $362 billion |
What to watch
Skyrizi and Rinvoq are the engines replacing Humira. Skyrizi treats psoriasis, Crohn’s disease, and ulcerative colitis. Rinvoq addresses rheumatoid arthritis and atopic dermatitis. Combined, these two drugs generated $17 billion in 2025 sales and are growing double digits annually.
AbbVie’s oncology pipeline includes Venclexta for blood cancers and Imbruvica for lymphoma. The neuroscience portfolio features Vraylar for bipolar disorder and depression. These diversification efforts reduce dependence on any single drug.
Investors should monitor the pace of Humira erosion. Biosimilar pricing pressure continues in the U.S. market after years of delayed competition. Management guidance suggests Humira will stabilize at a lower baseline but will not return to growth.
Analyst outlook for AbbVie
Analysts at Morgan Stanley maintain an “Overweight” rating on ABBV with a price target of $225. They cite Skyrizi and Rinvoq momentum as key growth drivers. Goldman Sachs assigns a fair value estimate of $218, noting the immunology franchise transition is proceeding ahead of schedule.
JP Morgan analysts point out that AbbVie’s aesthetics business through Allergan provides steady cash flow. They expect Botox therapeutic and cosmetic sales to grow 6 percent annually through 2028. The consensus view among surveyed firms suggests AbbVie can sustain mid-single-digit revenue growth while maintaining dividend coverage.
Dividend income comparison
| Stock | Price | Shares per $100K | Annual Income |
| AbbVie (ABBV) | $205.00 | 488 | $3,200 |
| Johnson & Johnson (JNJ) | $162.00 | 617 | $2,958 |
| Merck (MRK) | $115.00 | 870 | $2,958 |
Bottom line
AbbVie offers a 3.2 percent dividend yield with 52 consecutive years of increases. The company has successfully navigated patent cliffs before. Skyrizi and Rinvoq are already larger than Humira was at peak on a global basis.
The stock trades at a reasonable valuation for a pharmaceutical dividend aristocrat. Income investors seeking healthcare exposure should consider AbbVie as a defensive holding with pipeline upside. The dividend is well-covered by free cash flow and supported by a diversified revenue base.
Stay ahead with our weekly newsletter
Get stock picks, market analysis, and strategy updates delivered to your inbox every week.
Subscribe to AlphaBetaStock’s free newsletter for daily market insights.
